A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
Article
Manzo, Julia, Puhalla, Shannon, Pahuja, Shalu et al. (2022). A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 89(5), 721-735. 10.1007/s00280-022-04430-6
Manzo, Julia, Puhalla, Shannon, Pahuja, Shalu et al. (2022). A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer
. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 89(5), 721-735. 10.1007/s00280-022-04430-6